ALSO NOTED: Pfizer gets hit with $7B claim; Bavarian Nordic wins contract;and much more...

> Nigerian officials have now filed a $7 billion claim against Pfizer related to what it called illegal trials of an anti-meningitis therapy that left a number of children dead or disabled. Report

> Denmark's Bavarian Nordic has won a $500 million contract for a new generation of smallpox vaccine. Release

> Quark Pharmaceuticals says it will sell 5 million shares in its IPO at $12 to $14 a share. Report

> The FDA has approved Upsher-Smith Laboratories' Divigel (estradiol gel) 0.1 percent, the lowest approved dose of estradiol available for the treatment of moderate to severe hot flashes associated with menopause. Release

> Valeant Pharmaceuticals has signed an agreement to sell its manufacturing facilities in Humacao, Puerto Rico and Basel, Switzerland to Legacy Pharmaceuticals International. Release

> A team of British scientists say they can develop a stem cell therapy that will cure blindness caused by age-related macular degeneration within five years. Report

> Pouring through public records on file in Minnesota, The New York Times found more than 100 cases of physicians who were paid by drug companies to test therapies after they had been sanctioned by the state medical board for a variety of offenses, including the reckless disregard of their patients' welfare. Report

And Finally… Biotech balladeer and sell-side analyst Joel Sendek has composed, among others, a new ditty about Amgen's fading Erythropoietin. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.